Bill Flores sold Bristol-Myers Squibb Company (NYSE: BMY)
Bill Flores (R-TX), a U.S. Representative, has disclosed 1 trade in Bristol-Myers Squibb Company (BMY) since 2014, a single sale, worth an estimated $75K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a sale: Bill Flores sold $50,001 - $100,000 of Bristol-Myers Squibb Company (NYSE: BMY) on February 5, 2014. Since that trade, BMY is up +99.95% against the S&P 500 up +421.28%, an outperformance of -321.32%.
Data updated
Bill Flores's BMY trades vs the price
BMY is up +99.95% since Bill Flores sold on February 5, 2014, versus +421.28% for the S&P 500.
Performance since this trade
All Bill Flores BMY trades
Bill Flores & BMY trading FAQ
Is it legal for Bill Flores to trade Bristol-Myers Squibb Company (BMY) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Bristol-Myers Squibb Company (BMY), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Bill Flores sell BMY?
Bill Flores disclosed a sale of $50,001 - $100,000 of Bristol-Myers Squibb Company (BMY) on February 5, 2014, according to public STOCK Act filings.
How has BMY performed since Bill Flores's trade?
Since Bill Flores sold BMY on February 5, 2014, the stock is up +99.95%, versus +421.28% for the S&P 500 over the same period, an outperformance of -321.32%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional BMY trades?
Quantellect tracks every disclosed congressional trade in Bristol-Myers Squibb Company (BMY) on the Bristol-Myers Squibb Company congressional trading page, which aggregates filings across all members of Congress.
Bill Flores's BMY tradesAll congressional filings for Bristol-Myers Squibb CompanyBill Flores's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.